Joseph W. Leach

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

James L. Gulley, Arun Rajan, David R. Spigel et al. · The Lancet Oncology · 2017 · 284 citations · Full text

Medicine, Oncology, Pharmacology +14

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

Taofeek K. Owonikoko, Suzanne E. Dahlberg, Gabriel Sica et al. · Journal of Clinical Oncology · 2018 · 190 citations

Medicine, Oncology, Pharmacology +12

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

Steven I. Park, Steven M. Horwitz, Francine M. Foss et al. · Cancer · 2019 · 146 citations · Full text

Medicine, Oncology, Cancer Immunology +9